Related Experiment Video
Updated: Apr 11, 2026
09:07
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
12.8K
How predictable is the erectile function of patients with epilepsy?
Fábio Cavalcanti de Faria Vieira1, Marcelo Fernando Ronsoni2, Alexandre Hohl2
1Centro de Neurociências Aplicadas, Hospital Universitário, Universidade Federal de Santa Catarina (UFSC), Florianópolis, Brazil.
Epilepsy & Behavior : E&B
|June 5, 2015
Summary
Erectile dysfunction (ED) is common in epilepsy patients. Higher education, fewer depressive symptoms, and lower prolactin levels are linked to better erectile function, predicting up to 41% of cases.
Area of Science:
- Neurology
- Endocrinology
- Psychiatry
Background:
- Erectile dysfunction (ED) is frequently reported in epilepsy patients.
- Potential causes include endocrine issues, antiepileptic drug side effects, and psychological factors.
Purpose of the Study:
- To identify independent predictors of ED in individuals with epilepsy.
- To understand the factors contributing to ED in this population.
Main Methods:
- Utilized the International Index of Erectile Function (IIEF-5) questionnaire.
- Conducted multiple linear regression analysis on 36 focal epilepsy patients.
- Assessed factors including family income, education, depressive symptoms, and prolactin levels.
Main Results:
- ED prevalence was high among epilepsy patients.
- Factors like education level, depressive symptoms (HADS), and prolactin levels significantly predicted ED.
- These factors explained 41% of the variation in IIEF scores (r=0.64).
Conclusions:
- ED is highly prevalent in focal epilepsy.
- Education, depressive symptoms, and prolactin levels are key predictors of ED.
- Further research with larger sample sizes is warranted to identify biomarkers and therapeutic targets.
More Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
01:30Electroconvulsive Therapy
2.2K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
01:20Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
351
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
351
01:13Seizures: Classification
2.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.3K